简要报告：2018年至2024年美国心脏病专家和其他专科医生使用秋水仙碱的趋势。

IF 3.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal Pub Date : 2024-10-22 DOI:10.1016/j.ahj.2024.10.011

Michael Khorsandi MD , Omar Mhaimeed MD , Omar Dzaye MD, MPH, PhD , Erfan Tasdighi MD , G. Caleb Alexander MD, MS , Michael J. Blaha MD, MPH

{"title":"简要报告：2018年至2024年美国心脏病专家和其他专科医生使用秋水仙碱的趋势。","authors":"Michael Khorsandi MD , Omar Mhaimeed MD , Omar Dzaye MD, MPH, PhD , Erfan Tasdighi MD , G. Caleb Alexander MD, MS , Michael J. Blaha MD, MPH","doi":"10.1016/j.ahj.2024.10.011","DOIUrl":null,"url":null,"abstract":"<div><div>Colchicine has emerged as an effective agent for reducing ASCVD based on recent large cardiovascular outcome trials and exerts its benefit through targeting inflammation. In light of the robust body of data and FDA approval of low-dose colchicine for ASCVD prevention, this paper aimed to use the National Prescription Audit to quantify the volume and trends of colchicine prescriptions dispensed through U.S. retail pharmacies between March 2018 and February 2024. Despite a 6% increase in total monthly prescriptions since 2020, which was driven primarily by cardiologists, this specialty still represents only 2.8%-4% of the national monthly precription totals with small absolute numbers (ie estimated ∼4000 incremental prescriptions/month since 2020), suggesting limited cardiologist adoption of colchicine for ASCVD prevention despite favorable clinical trial data.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 76-80"},"PeriodicalIF":3.7000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024\",\"authors\":\"Michael Khorsandi MD , Omar Mhaimeed MD , Omar Dzaye MD, MPH, PhD , Erfan Tasdighi MD , G. Caleb Alexander MD, MS , Michael J. Blaha MD, MPH\",\"doi\":\"10.1016/j.ahj.2024.10.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Colchicine has emerged as an effective agent for reducing ASCVD based on recent large cardiovascular outcome trials and exerts its benefit through targeting inflammation. In light of the robust body of data and FDA approval of low-dose colchicine for ASCVD prevention, this paper aimed to use the National Prescription Audit to quantify the volume and trends of colchicine prescriptions dispensed through U.S. retail pharmacies between March 2018 and February 2024. Despite a 6% increase in total monthly prescriptions since 2020, which was driven primarily by cardiologists, this specialty still represents only 2.8%-4% of the national monthly precription totals with small absolute numbers (ie estimated ∼4000 incremental prescriptions/month since 2020), suggesting limited cardiologist adoption of colchicine for ASCVD prevention despite favorable clinical trial data.</div></div>\",\"PeriodicalId\":7868,\"journal\":{\"name\":\"American heart journal\",\"volume\":\"279 \",\"pages\":\"Pages 76-80\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American heart journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002870324002734\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324002734","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

根据最近的大型心血管结果试验，秋水仙碱已成为一种有效的降低心血管急性发作危险的药物，并通过靶向炎症发挥其疗效。鉴于大量数据以及美国食品及药物管理局批准小剂量秋水仙碱用于预防 ASCVD，本文旨在利用国家处方审核系统（National Prescription Audie）量化 2018 年 3 月至 2024 年 2 月期间美国零售药店开出的秋水仙碱处方数量和趋势。尽管自 2020 年以来，每月处方总量增加了 6%，主要由心脏病专家推动，但该专科仍仅占全国每月总量的 2.8-4%，绝对数量较少（即自 2020 年以来，估计每月处方增量为 4000 个），这表明尽管临床试验数据良好，但心脏病专家采用秋水仙碱预防 ASCVD 的程度有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024

查看原文本刊更多论文

Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024

Colchicine has emerged as an effective agent for reducing ASCVD based on recent large cardiovascular outcome trials and exerts its benefit through targeting inflammation. In light of the robust body of data and FDA approval of low-dose colchicine for ASCVD prevention, this paper aimed to use the National Prescription Audit to quantify the volume and trends of colchicine prescriptions dispensed through U.S. retail pharmacies between March 2018 and February 2024. Despite a 6% increase in total monthly prescriptions since 2020, which was driven primarily by cardiologists, this specialty still represents only 2.8%-4% of the national monthly precription totals with small absolute numbers (ie estimated ∼4000 incremental prescriptions/month since 2020), suggesting limited cardiologist adoption of colchicine for ASCVD prevention despite favorable clinical trial data.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American heart journal 医学-心血管系统

CiteScore

8.20

自引率

2.10%

发文量

214

审稿时长

38 days

期刊介绍： The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.